ERBB2 and breast cancer: Based on these premises, clinical trials testing immunotherapy in the early setting, mostly as neoadjuvant strategy in BC patients with HER2+ disease have been initiated (NCT03595592; NCT03726879; NCT03515798) and results are pending.